TNF-alpha: a key to Crohn's disease

Crohn's disease causes the immune system to produce too much of the TNF-alpha (tumor necrosis factor-alpha) protein.1 This can lead to painful, inconvenient symptoms and damage to the gastrointestinal tract.2

CIMZIA targets both membrane-bound and soluble human TNF-alpha.3

CIMZIA targets TNF-alpha

CIMZIA is a biologic medication that targets the TNF-alpha protein, blocking it from causing inflammation.3 CIMZIA is only PEGylated anti-TNF medication.1,3-6

  • CIMZIA is composed of the Fab' antigen-binding domain of a humanized anti-TNF antibody, site-specifically bound to polyethylene glycol (PEG) so that it does not interfere with TNF binding. In studies, CIMZIA was shown to bind with and neutralize both membrane-bound and soluble human TNF-alpha in a dose-dependent manner.3
  • CIMZIA does not fix complement or induce antibody-dependent cell-mediated cytotoxicity in vitro. The clinical relevance of in vitro findings is unknown. CIMZIA also does not induce apoptosis or neutrophil degranulation.3
  • CIMZIA is administered by subcutaneous injection and is designed so it can be dosed on an every 4 weeks basis after initial dosing.3

Watch a video to learn more

Indication
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Important Safety Information
Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.

Anaphylaxis or serious allergic reactions may occur. Hypersensitivity reactions have been reported rarely following CIMZIA administration.

NEXT: PEGylated Technology »